These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 8909011)

  • 21. Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer GFPC 99-01 study (Groupe français de pneumo-cancérologie).
    Thomas P; Robinet G; Gouva S; Fournel P; Léna H; Le Caer H; Perol M; Berard H; Bombaron P; Vergnenegre A; Kleisbauer JP;
    Lung Cancer; 2006 Jan; 51(1):105-14. PubMed ID: 16310886
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of vinorelbine alone or vinorelbine plus cisplatin for stage IV NSCLC.
    Evans WK
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 4):18-25; discussion 25-6. PubMed ID: 9556779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group.
    Pectasides D; Kalofonos HP; Samantas E; Nicolaides C; Papacostas P; Onyenadum A; Visvikis A; Skarlos D; Fountzilas G
    Anticancer Res; 2001; 21(4B):3005-10. PubMed ID: 11712802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized phase II trial of sequential gemcitabine plus vinorelbine followed by gemcitabine plus ifosfamide versus gemcitabine plus cisplatin in the treatment of chemo-naive patients with stages III and IV non-small cell lung cancer (NSCLC).
    Grigorescu A; Ciuleanu T; Firoiu E; Muresan DR; Teodorescu G; Basson BR
    Lung Cancer; 2007 Aug; 57(2):168-74. PubMed ID: 17467848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.
    Comella P; Frasci G; De Cataldis G; Panza N; Cioffi R; Curcio C; Belli M; Bianco A; Ianniello G; Maiorino L; Della Vittoria M; Perchard J; Comella G
    Br J Cancer; 1996 Dec; 74(11):1805-11. PubMed ID: 8956797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer.
    Thongprasert S; Permsuwan U; Ruengorn C; Charoentum C; Chewaskulyong B
    Asia Pac J Clin Oncol; 2011 Dec; 7(4):369-75. PubMed ID: 22151987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial.
    Alberola V; Camps C; Provencio M; Isla D; Rosell R; Vadell C; Bover I; Ruiz-Casado A; Azagra P; Jiménez U; González-Larriba JL; Diz P; Cardenal F; Artal A; Carrato A; Morales S; Sanchez JJ; de las Peñas R; Felip E; López-Vivanco G;
    J Clin Oncol; 2003 Sep; 21(17):3207-13. PubMed ID: 12947054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Costs of first-line doublet chemotherapy and lifetime medical care in advanced non-small-cell lung cancer in the United States.
    Lang K; Marciniak MD; Faries D; Stokes M; Buesching D; Earle C; Treat J; Babineaux S; Morissette N; Thompson D
    Value Health; 2009 Jun; 12(4):481-8. PubMed ID: 18980633
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens.
    Kosmas C; Tsavaris N; Panopoulos C; Vadiaka M; Stavroyianni N; Kourelis T; Malamos N; Antonopoulos M; Kalofonos HP
    Eur J Cancer; 2001 May; 37(8):972-8. PubMed ID: 11334721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic evaluation of gemcitabine alone and in combination with cisplatin in the treatment of nonsmall cell lung cancer.
    Lees M; Aristides M; Maniadakis N; McKendrick J; Botwood N; Stephenson D
    Pharmacoeconomics; 2002; 20(5):325-37. PubMed ID: 11994042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer.
    Stewart DJ; Tomiak E; Shamji FM; Maziak DE; MacLeod P
    Lung Cancer; 2004 May; 44(2):241-9. PubMed ID: 15084389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost analysis of hospital treatment--two chemotherapic regimens for non-surgical non-small cell lung cancer. GFPC (Groupe Français Pneumo Cancérologie).
    Vergnenègre A; Perol M; Pham E
    Lung Cancer; 1996 Feb; 14(1):31-44. PubMed ID: 8696719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST).
    Boni C; Tiseo M; Boni L; Baldini E; Recchia F; Barone C; Grossi F; Germano D; Matano E; Marini G; Labianca R; Di Costanzo F; Bagnulo A; Pennucci C; Caroti C; Mencoboni M; Zanelli F; Prochilo T; Cafferata MA; Ardizzoni A;
    Br J Cancer; 2012 Feb; 106(4):658-65. PubMed ID: 22240782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized study of gemcitabine plus cisplatin and vinorelbine plus cisplatin in patients with advanced non-small-cell lung cancer.
    Chang JW; Tsao TC; Yang CT; Lin MC; Cheung YC; Liaw CC; Chen CH
    Chang Gung Med J; 2008; 31(6):559-66. PubMed ID: 19241895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer.
    Ramsey SD; Moinpour CM; Lovato LC; Crowley JJ; Grevstad P; Presant CA; Rivkin SE; Kelly K; Gandara DR
    J Natl Cancer Inst; 2002 Feb; 94(4):291-7. PubMed ID: 11854391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group.
    Rudd RM; Gower NH; Spiro SG; Eisen TG; Harper PG; Littler JA; Hatton M; Johnson PW; Martin WM; Rankin EM; James LE; Gregory WM; Qian W; Lee SM
    J Clin Oncol; 2005 Jan; 23(1):142-53. PubMed ID: 15625369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancer.
    Copley-Merriman C; Corral J; King K; Whiteside R; Voi M; Dorr FA; McDonald RC
    Lung Cancer; 1996 Feb; 14(1):45-61. PubMed ID: 8696720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer.
    Bunn PA
    Semin Oncol; 1999 Feb; 26(1 Suppl 4):25-30. PubMed ID: 10201518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of vinorelbine, ifosfamide, and cisplatin combination chemotherapy in advanced non-small-cell lung cancer.
    Ahn JB; Ko WK; Lee JG; Shim KY; Jeung HC; Park JO; Yoo NC; Kim BS; Kim SK; Kim SK; Kim JH
    Am J Clin Oncol; 2000 Dec; 23(6):622-8. PubMed ID: 11202811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project.
    Crinò L; Scagliotti GV; Ricci S; De Marinis F; Rinaldi M; Gridelli C; Ceribelli A; Bianco R; Marangolo M; Di Costanzo F; Sassi M; Barni S; Ravaioli A; Adamo V; Portalone L; Cruciani G; Masotti A; Ferrara G; Gozzelino F; Tonato M
    J Clin Oncol; 1999 Nov; 17(11):3522-30. PubMed ID: 10550150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.